Literature DB >> 3389643

Survival and causes of death in hemochromatosis. Observations in 163 patients.

G Strohmeyer1, C Niederau, W Stremmel.   

Abstract

Survival and causes of death were analyzed among 163 patients with hemochromatosis diagnosed between 1959 and 1983. Mean followup was 10.5 +/- 5.6 years (+/- SD). Cumulative survival was 76% at 10 years and 49% at 20 years. Life expectancy was reduced in patients who presented with cirrhosis or diabetes compared to patients who presented without these complications at the time of diagnosis. Patients who could be depleted of iron during the first 18 months of venesection therapy had a markedly better prognosis compared to those patients who could not be depleted during this time period, probably due to greater amounts of excessive iron. Prognosis was not influenced by sex. Patients without cirrhosis or diabetes had a life expectancy that was virtually identical to that of an age-matched normal population. Analysis of the causes of death in 53 patients showed that liver cancer (n = 16) was 219 times more frequent, cardiomyopathy (n = 3) was 306 times more frequent, liver cirrhosis (n = 10) was 13 times more frequent, and diabetes mellitus (n = 3) was seven times more frequent compared to death rates expected for an age-matched normal population. The risk of death from other causes, including extrahepatic cancer (n = 7), did not differ from rates expected. Thus, patients with hemochromatosis diagnosed in a precirrhotic stage and treated by venesection have a normal life expectancy. Cirrhotic patients had a shortened life expectancy and a high risk of death from liver cancer even when complete iron depletion has been achieved.

Entities:  

Mesh:

Year:  1988        PMID: 3389643     DOI: 10.1111/j.1749-6632.1988.tb55510.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 2.  Non-viral causes of hepatocellular carcinoma.

Authors:  Wojciech Blonski; David S Kotlyar; Kimberly A Forde
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 3.  Overview of hemochromatosis.

Authors:  L H Smith
Journal:  West J Med       Date:  1990-09

Review 4.  Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis.

Authors:  P Wainwright; E Scorletti; C D Byrne
Journal:  Curr Diab Rep       Date:  2017-04       Impact factor: 4.810

5.  Effects of strain and age on hepatic gene expression profiles in murine models of HFE-associated hereditary hemochromatosis.

Authors:  Seung-Min Lee; Alexandre Loguinov; Robert E Fleming; Christopher D Vulpe
Journal:  Genes Nutr       Date:  2014-11-27       Impact factor: 5.523

6.  Prognosis and life expectancy in chronic liver disease.

Authors:  A Propst; T Propst; G Zangerl; D Ofner; G Judmaier; W Vogel
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

7.  HFE mutations in heart disease.

Authors:  Terence Dunn; Derek Blankenship; Nicole Beal; Richard Allen; Eliot Schechter; William Moore; Ghazala Perveen; June Eichner
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

Review 8.  Hepatic iron overload and hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

9.  Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis.

Authors:  R W Sallie; W D Reed; K B Shilkin
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

Review 10.  MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled.

Authors:  Catherine M Greene; Robert B Varley; Matthew W Lawless
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.